Monte Rosa Therapeutics (GLUE) Price & Analysis

Compare

303 Followers

GLUE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.50 - $12.40

Previous CloseN/A

Volume283.19K

Average Volume (3M)400.32K

Market Cap

$303.24M

Enterprise Value$121.20M

Total Cash (Recent Filing)$290.59M

Total Debt (Recent Filing)$41.13M

Price to Earnings (P/E)14.3

Beta1.95

Next Earnings

Nov 06, 2025

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding61,759,350

10 Day Avg. Volume344,383

30 Day Avg. Volume400,324

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.40

Enterprise Value/Revenue0.68

Enterprise Value/Gross Profit0.71

Enterprise Value/Ebitda5.72

Forecast

1Y Price Target

$20.00

Price Target Upside307.33% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Cash ReservesMonte Rosa Therapeutics has a substantial cash reserve of $296MM, providing a financial runway into 2028.

Financial MilestonesMonte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones, beginning upon the initiation of the Phase 2 studies.

PartnershipsMonte Rosa's lead I&I asset, MRT-6160, is advancing toward multiple Phase 2 trials, supported through a partnership with Novartis.

Bears Say

Data RequirementThere is a need for additional clinical data to inform views on MRT-2359's potential indications in MYC-expressing tumors, as the focus narrows to CRPC and HR+ breast cancer.

Market SentimentShort interest in Monte Rosa is at 30.6% of the float.

Revenue ForecastingIt's currently challenging to forecast the precise development paths and subsequent potential revenues for the assets.

Monte Rosa Therapeutics News

Monte Rosa Therapeutics reports Q2 revenue $23.194M, consensus $7.37M

“With the advancement of our third program into clinical development, we continue to efficiently execute across our portfolio...

30d ago

GLUE

Monte Rosa Therapeutics Reports Q2 2025 Earnings

Monte Rosa Therapeutics, Inc. ( ($GLUE) ) has released its Q2 earnings. Here is a breakdown of the...

29d ago

GLUE

Buy Rating for Monte Rosa Therapeutics: Promising Pipeline and Strategic Partnerships Drive Growth Potential

LifeSci Capital analyst Oliver McCammon has maintained their bullish stance on GLUE stock, giving a Buy rating today....

29d ago

GLUE

Monte Rosa Therapeutics management to meet with Piper Sandler

Meeting to be held in Boston on July 22 hosted by Piper Sandler. Published first on TheFly –...

2M ago

GLUE

Monte Rosa announces first subjects dosed in Phase 1 study of MRT-8102

Monte Rosa Therapeutics (GLUE) announced that the first subjects have been dosed in a Phase 1 study evaluating...

2M ago

GLUE

Monte Rosa Therapeutics announces FDA clearance of IND application for MRT-8102

Monte Rosa Therapeutics (GLUE) announced U.S. Food and Drug Administration, FDA, clearance of an Investigational New Drug, IND,...

3M ago

GLUE

Buy Rating for Monte Rosa Therapeutics: Promising Pipeline and Strategic Partnerships Drive Positive Outlook

LifeSci Capital analyst Oliver McCammon has maintained their bullish stance on GLUE stock, giving a Buy rating today....

4M ago

GLUE

Monte Rosa Therapeutics Reports Strong Q1 2025 Earnings

Monte Rosa Therapeutics, Inc. ( ($GLUE) ) has released its Q1 earnings. Here is a breakdown of the...

4M ago

GLUE

Monte Rosa Therapeutics: Promising Developments and Financial Stability Support Buy Rating

TD Cowen analyst Marc Frahm has maintained their bullish stance on GLUE stock, giving a Buy rating on...

4M ago

GLUE

Monte Rosa Therapeutics Reports Strong Q1 2025 Results

Monte Rosa Therapeutics ( ($GLUE) ) has provided an update. Monte Rosa Therapeutics announced its first-quarter 2025 financial...

4M ago

GLUE

Monte Rosa Therapeutics reports Q1 revenue $84.929M vs $1.064M last year

“We’ve made significant progress across our entire portfolio in the development of our only-in-class and first-in-class molecular glue...

4M ago

GLUE

Promising Developments in Cancer Treatment: Monte Rosa Therapeutics’ MRT-51443 Gains Buy Rating

Analyst Oliver McCammon from LifeSci Capital maintained a Buy rating on Monte Rosa Therapeutics (GLUE – Research Report)...

4M ago

GLUE

Monte Rosa Therapeutics presents preclinical data at AACR on MRT-51443

Monte Rosa Therapeutics (GLUE) announced the company will present preclinical data on the potential of its highly selective...

4M ago

GLUE

Monte Rosa Therapeutics Earnings Call Highlights Progress and Strategic Shifts

Monte Rosa Therapeutics, Inc. (($GLUE)) has held its Q4 earnings call. Read on for the main highlights of...

6M ago

GLUE

GLUE FAQ

What was Monte Rosa Therapeutics’s price range in the past 12 months?

Monte Rosa Therapeutics lowest stock price was $3.50 and its highest was $12.40 in the past 12 months.

What is Monte Rosa Therapeutics’s market cap?

Monte Rosa Therapeutics’s market cap is $303.24M.

When is Monte Rosa Therapeutics’s upcoming earnings report date?

Monte Rosa Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 61 days.

How were Monte Rosa Therapeutics’s earnings last quarter?

Monte Rosa Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.377 by $0.227.

Is Monte Rosa Therapeutics overvalued?

According to Wall Street analysts Monte Rosa Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Monte Rosa Therapeutics pay dividends?

Monte Rosa Therapeutics does not currently pay dividends.

What is Monte Rosa Therapeutics’s EPS estimate?

Monte Rosa Therapeutics’s EPS estimate is -0.33.

How many shares outstanding does Monte Rosa Therapeutics have?

Monte Rosa Therapeutics has 61,759,350 shares outstanding.

What happened to Monte Rosa Therapeutics’s price movement after its last earnings report?

Monte Rosa Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.377. Following the earnings report the stock price went down -2.982%.

Which hedge fund is a major shareholder of Monte Rosa Therapeutics?

Currently, no hedge funds are holding shares in GLUE

Monte Rosa Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

9.81%

Trailing 12-Months

Asset Growth

4.50%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Monte Rosa Therapeutics (GLUE) Earnings & Revenues

Historic Earnings Reports

GLUE Stock 12 Month Forecast

Average Price Target

$20.00

▲(307.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","12":"$12","21":"$21","7.5":"$7.5","16.5":"$16.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,7.5,12,16.5,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.79,5.96,7.130000000000001,8.3,9.47,10.64,11.810000000000002,12.98,14.150000000000002,15.32,16.490000000000002,17.66,18.830000000000002,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.79,5.96,7.130000000000001,8.3,9.47,10.64,11.810000000000002,12.98,14.150000000000002,15.32,16.490000000000002,17.66,18.830000000000002,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.79,5.96,7.130000000000001,8.3,9.47,10.64,11.810000000000002,12.98,14.150000000000002,15.32,16.490000000000002,17.66,18.830000000000002,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.94,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.17,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.94,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.79,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >